SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Silence Therapeutics plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$19.58+10.90 (+125.58%)
Close on Oct 19, 2026
- Market cap
- $2.77B
- P/E (TTM)
- –
- Dividend yield
- –
Silence Therapeutics plc revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Research Collaboration | $559.00K | $43.11M | $30.93M | $20.94M | 100.0% | -98.7% |
| Royalties | $0 | $144.00K | $710.00K | $715.00K | 0.0% | -100.0% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| United Kingdom | $559.00K | $43.11M | $30.93M | $20.94M | 100.0% | -98.7% |
| Germany | – | $144.00K | $709.00K | $715.00K | – | – |
From the segment and revenue-disaggregation notes of Silence Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.